生物
TFAM公司
DNA甲基转移酶
DNA甲基化
线粒体DNA
分子生物学
DNMT1型
干扰素
突变
转录因子
表观遗传学
体细胞
DNA
DNA损伤
Ⅰ型干扰素
基因
癌症研究
细胞生物学
遗传学
基因表达
作者
Isidoro Cobo,Tiffany Tanaka,Kailash Chandra Mangalhara,Addison J. Lana,Calvin Yeang,Claudia Z. Han,Johannes C. M. Schlachetzki,Jean Challcombe,Bethany Fixsen,Mashito Sakai,Rick Z. Li,Hannah Fields,Michal Mokrý,Randy Guo-Shi Tsai,Rafael Bejar,Koen H.M. Prange,Menno P.J. de Winther,Gerald S. Shadel,Christopher K. Glass
出处
期刊:Immunity
[Cell Press]
日期:2022-08-01
卷期号:55 (8): 1386-1401.e10
被引量:55
标识
DOI:10.1016/j.immuni.2022.06.022
摘要
Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2 resulted in a type I interferon response due to impaired mitochondrial DNA integrity and activation of cGAS signaling. DNMT3A and TET2 normally maintained mitochondrial DNA integrity by regulating the expression of transcription factor A mitochondria (TFAM) dependent on their interactions with RBPJ and ZNF143 at regulatory regions of the TFAM gene. These findings suggest that targeting the cGAS-type I IFN pathway may have therapeutic value in reducing risk of CVD in patients with DNMT3A or TET2 mutations.
科研通智能强力驱动
Strongly Powered by AbleSci AI